Although all three studies demonstrated overall improvements in ALT levels, suggesting an improvement in liver function, variations in statistical significance and differences across NAFLD stages underscore the need for more comprehensive research to better understand GSH’s efficacy and its impact on different disease severities. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.